Detalles de la búsqueda
1.
Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis.
Value Health
; 26(12): 1689-1696, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37741447
2.
Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US.
Oncologist
; 27(11): 907-918, 2022 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35925602
3.
Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study.
Eur J Haematol
; 109(1): 58-68, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35298049
4.
Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild-type acute myeloid leukemia: A medical chart study.
Eur J Haematol
; 102(4): 341-350, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30578743
5.
Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs).
Clin Lymphoma Myeloma Leuk
; 24(3): 177-186, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37996264
6.
Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis.
Curr Oncol
; 29(10): 7524-7536, 2022 10 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36290869
7.
Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.
J Manag Care Spec Pharm
; 28(9): 980-988, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35708343
8.
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia.
Blood Cancer J
; 12(4): 71, 2022 04 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35443742
9.
Treatment patterns in patients with acute myeloid leukemia in the United States: a cross-sectional, real-world survey.
Curr Med Res Opin
; 35(5): 927-935, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30712406
10.
Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
J Med Econ
; 20(2): 121-128, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27570999
11.
Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
J Manag Care Spec Pharm
; 22(2): 163-70, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27015255
12.
Resource utilization and use of life-extending therapies and corticosteroids in prostate cancer patients with corticosteroid-sensitive comorbidities.
Curr Med Res Opin
; 30(11): 2355-64, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25133961
13.
Antimuscarinic use among individuals with urinary incontinence who reside in long-term care facilities.
Int Urol Nephrol
; 46(1): 285-96, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23943373
14.
Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder.
J Med Econ
; 15 Suppl 1: 35-44, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22998646
Resultados
1 -
14
de 14
1
Próxima >
>>